Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment

This study has been withdrawn prior to enrollment.
(The PI left the institution.)
Sponsor:
Collaborator:
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00167557
First received: September 9, 2005
Last updated: November 18, 2013
Last verified: November 2013

September 9, 2005
November 18, 2013
January 2005
March 2008   (final data collection date for primary outcome measure)
Viral clearance after liver transplantation [ Time Frame: 3 yrs. post liver transplant ] [ Designated as safety issue: No ]
Viral clearance after liver transplantation
Complete list of historical versions of study NCT00167557 on ClinicalTrials.gov Archive Site
  • histological progression of fibrosis and inflammation [ Time Frame: 3 yrs. post liver transplant ] [ Designated as safety issue: Yes ]
  • rate of rejection on HCV treatment [ Time Frame: 3 yrs post liver transplant ] [ Designated as safety issue: No ]
  • Complication rate of HCV treatment
  • histological progression of fibrosis and inflammation
  • rate of rejection on HCV treatment
Not Provided
Not Provided
 
Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment
Tacrolimus Monotherapy in OLT Recipients With HCV Under Preemptive Treatment With Interferon and Ribavirin

After a liver transplant, the hepatitis C virus (which destroyed one's own liver) eventually comes back. In many patients, this will eventually cause the loss of the new liver and can also confuse the doctors taking care of them because it is hard to tell the difference between one's body rejecting the new liver and hepatitis. This can cause serious treatment errors that can lead to more severe hepatitis or to rejection of the liver. Some of the drugs used to prevent rejection of one's new liver can cause the hepatitis to come back in a more severe form. This is especially true for the drugs known as corticosteroids.

Right now, the only effective treatment against hepatitis C is a combination of two drugs called interferon and ribavirin. These drugs act by strengthening one's immune system to fight the virus and by directly reducing the reproduction of the virus. Because the treatment with these drugs is associated with many side effects, there is little experience with treating patients after liver transplantation with them.

In the investigators' transplant program, they have decided to treat all patients with hepatitis C as early as possible after transplantation and to follow them closely for the development of hepatitis and side effects of the treatment. The investigators treat one's hepatitis as early as possible, before any actual damage has occurred in the new liver. This approach has been tried before but it has been hard to tell if it has worked or not. The main reason for failure was that many patients could not complete the treatment due to side effects. The investigators' purpose is to treat those side effects aggressively so that most patients can complete the treatment course.

The purpose of this study is to collect all the data regarding the investigators' treatment protocol so that they will be able to learn if this form of treatment is beneficial.

The study includes performing liver biopsies at scheduled times after one's liver transplant and for scheduled blood tests to see how much virus is still in the blood. If patients show signs that they are not responding to treatment they will be removed from the study.

HCV recurs in the transplanted liver almost invariably. The clinical course is variable and ranges from no hepatitis to severe aggressive hepatitis with cirrhosis. Factors that affect outcome are high viral load prior to OLT, genotype, and immunosuppressive regimen. Recent studies indicate that the severity of recurrence is increasing with longer follow up, and longevity of both graft and patient is compromised by HCV. Viral load appears to be particularly affected by corticosteroids. The impact of mycophenolate mofetil and tacrolimus is not certain. The results of re-transplantation are generally poor and seem to be a non-cost beneficial way to deal with recurrence HCV cirrhosis. Additionally, re-transplantation deprives other patients from getting OLT in a timely fashion.

Recent studies have shown that with intensive alpha interferon and ribavirin treatment, up to 40% of patients can be cleared of virus as measured by PCR. Thus, despite the cost and side effects of this treatment, it appears justified to treat recurrence preemptively.

Due to the deleterious effects of high dose Corticosteroids it seems logical to attempt to withdraw them as soon as possible from treatment. MMF is often incompatible with interferon and ribavirin treatment due to leukopenia and anemia. The same is true for sirolimus. Thus, most patients will eventually be treated with Tacrolimus monotherapy. Presently, numerous patients end up being treated with Tacrolimus monotherapy as part of the reduction in immune suppression, which occurs over time. There is, however, very little prospective data regarding Tacrolimus monotherapy and almost no data on the specific issue of monotherapy in HCV patients. Even less is known with respect to this type of treatment while using interferon and ribavirin.

Our purpose in this protocol is to examine both the effect of preemptive antiviral treatment on recurrent HCV and the effect of Tacrolimus monotherapy in this setting. This may be important as more and more programs are turning to preemptive anti viral treatment and the issue of appropriate immune suppression becomes seminal to this discussion.

Aims

  1. To determine the safety and efficacy of PEG interferon and ribavirin in the treatment of HCV recurrence after OLT.
  2. To determine the effectiveness and safety of maintenance dose of PEG interferon to delay progression of fibrosis and histologic damage, in non-responders to the initial regimen of PEG interferon and ribavirin.
  3. To determine the effect of early prednisone withdrawal in the rate of response to treatment with PEG interferon and ribavirin.
  4. To assess the feasibility of Tacrolimus monotherapy in patients undergoing treatment for HCV recurrence post transplant.
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatitis C
  • Drug: Pegylated Interferon
    180mcg SC weekly starting 30 days post transplant
  • Drug: Ribavirin
    goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
  • Procedure: Liver Biopsy
    Liver biopsies performed at 9 points in time from time of liver transplant
Experimental: Single Arm Study
Interventions:
  • Drug: Pegylated Interferon
  • Drug: Ribavirin
  • Procedure: Liver Biopsy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
March 2008
March 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Adult male or female patients between 18 and 70 years of age
  2. All liver transplant patients with a positive HCV RNA by PCR within 30 days after transplant.
  3. No evidence of acute or chronic rejection within 4 weeks of enrollment
  4. Compensated liver disease according to the following criteria:

    • Hemoglobin > 10 gm/dL;
    • Neutrophil count > 1,000/mm3;
    • Platelet count > 50,000/mm3;
    • Serum creatinine < 2.0 mg/dL.
  5. Documentation of adequate contraception in females and males sexually active or of childbearing potential.

Exclusion Criteria:

  1. Hypersensitivity to alpha interferon and/or ribavirin
  2. Previous treatment with interferon and/or ribavirin post liver transplantation
  3. HIV
  4. Autoimmune hepatitis
  5. Active alcohol or substance abuse
  6. Non compliance
  7. Hemoglobinopathies or hemolytic anemia
  8. Clinical significant retinal abnormalities
  9. Decompensated cardio-vascular, endocrine, pulmonary, renal, immune, metabolic, dermatologic or psychiatric illness
  10. Re-transplantation
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00167557
HSC-MS-04-0346, Astellas Pharma, FHIprojectno.JK-04-002
No
The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
Astellas Pharma US, Inc.
Principal Investigator: Hadar J Merhav, MD The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP